NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immunocore Holdings plc (IMCR) Stock Analysis

Immunocore Holdings plc (IMCR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMCR

$36.13

−$1.44 (−3.83%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMCR with… →

IMCR Key Statistics

As of Sep 4, 2026
Trading
Open
$37.24
Previous Close
$37.57
Day's Range
35.98–37.43
52-Week Range
27.56–40.72
Volume
231.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.74
Valuation
Market Cap
$1.86B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.36
Financials (FY)
Revenue (FY)
$400.02M+28.95%
Net Income (FY)
−$35.51M
Profit marginThe share of revenue left as profit after all costs and taxes.
−4.20%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.50M
1-Year Return
+2.47%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
517.49K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMCR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+4.09%
2025+17.66%
2024−56.82%
2023+19.71%
2022+66.68%
2021 (partial year)−20.74%

As of September 4, 2026.

IMCR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$400.02M−$35.51M−8.9%
2024$310.20M−$51.09M−16.5%
2023$249.43M−$55.29M−22.2%
2022$174.36M−$52.54M−30.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$400.02M$394.93M−$45.35M−$35.51M−8.9%
2024$310.20M$307.47M−$70.46M−$51.09M−16.5%
2023$249.43M$248.39M−$59.65M−$55.29M−22.2%
2022$174.36M$173.27M−$51.71M−$52.54M−30.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMCR Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMCRBiotechnology medianvs median
P/S ratio4.3215.260.3x the median
Profit margin−4.20%0.00%4.2 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immunocore Holdings plc (IMCR) carries a market capitalisation of $1.86B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 524.

IMCR last closed at $36.13 on September 4, 2026. That is −$1.44 (−3.83%) against the previous close. Over the past 52 weeks the price has ranged from $27.56 to $40.72. The latest close sits 31.12% above that 52-week low.

Financial Health

In fiscal 2025, Immunocore Holdings plc reported revenue of $400.02M. Against the prior fiscal year total of $310.20M, that is a change of +28.95%. The same year closed with a net loss of $35.51M. The reported profit margin is −4.2%. That is 4.2 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.36.

Across the 4 fiscal years on file, revenue moves from $174.36M in 2022 to $400.02M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.32. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +2.47%. Across 5 years the annualized return works out at +1.74%. The reported beta is 0.74. Daily returns over the trailing 5 years annualize to a volatility of 49.34%.

Growth & Income

The record shows no dividend for IMCR.

Across the complete calendar years on file, 2022 returned +66.68% and 2024 returned −56.82%. Of the 4 complete calendar years on file, 3 finished higher. So far in 2026 the price is +4.09%.

Peer Comparison

Immunocore Holdings plc (IMCR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immunocore Holdings plc IMCR $1.86B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immunocore Holdings plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immunocore Holdings plc

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Visit website →